CliffBio
biologic

Imlygic

Talimogene laherparepvec

Loss of exclusivityOctober 2027projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameImlygic
Active ingredientTalimogene laherparepvec
Strength1 MILLION PFU/ML
Dosage formFor Injection
RouteIntralesional
ModalityBiologic
FDA approvalOctober 2015
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.